about
Stroma cell-derived factor-1α signaling enhances calcium transients and beating frequency in rat neonatal cardiomyocytesRole of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target.Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.SDF1-induced antagonism of axonal repulsion requires multiple G-protein coupled signaling components that work in parallelQuantitative phosphoproteomics of CXCL12 (SDF-1) signaling.Patient-specific data fusion defines prognostic cancer subtypesCXCR4 expression in feline mammary carcinoma cells: evidence of a proliferative role for the SDF-1/CXCR4 axis.The emerging role of CXC chemokines and their receptors in cancer.Discovery and computer aided potency optimization of a novel class of small molecule CXCR4 antagonists.Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.CXCR4 Antagonists: A Screening Strategy for Identification of Functionally Selective Ligands.Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth.Targeting brain tumor cAMP: the case for sex-specific therapeutics5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype.First trimester screening of circulating C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia and IUGRThe Role of chemokine receptor CXCR4 in breast cancer metastasisInhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone.PDZ-RhoGEF is essential for CXCR4-driven breast tumor cell motility through spatial regulation of RhoA.Chemokines and the microenvironment in neuroectodermal tumor-host interactionChemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and PathologyNovel molecular events in oral carcinogenesis via integrative approaches.The role of chemokines and their receptors in angiogenesis.CXCL12/CXCR4 axis in the pathogenesis of acute lymphoblastic leukemia (ALL): a possible therapeutic target.Hybrid cells derived from breast epithelial cell/breast cancer cell fusion events show a differential RAF-AKT crosstalk.CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.Arsenic trioxide inhibits CXCR4-mediated metastasis by interfering miR-520h/PP2A/NF-κB signaling in cervical cancer.sPAGM: inferring subpathway activity by integrating gene and miRNA expression-robust functional signature identification for melanoma prognoses.Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 Antagonists.Reprogramming Medulloblastoma-Propagating Cells by a Combined Antagonism of Sonic Hedgehog and CXCR4.A single amino acid substitution in CXCL12 confers functional selectivity at the beta-arrestin level.Peptides targeting chemokine receptor CXCR4: structural behavior and biological binding studies
P2860
Q27315347-2DE16DFB-33E7-4EE7-A594-7E3DD9A3AD68Q33559560-4CC1B38B-8F78-474B-AB36-F807EB3A17DBQ33564854-C68B3CDE-F76A-43B6-B9EE-599BF7C30BE5Q33893771-2EF726B5-0415-4EF8-A68B-1D6FDE50C8A4Q34031600-69DD3F7F-D49C-43DE-A582-7626E4F806FBQ34058053-9FB86F07-405C-44C5-A770-191E2D8A384BQ34195197-33449977-76E2-4526-81D5-FDEC1E4DD808Q34263645-A1453322-907B-4F98-83EF-B7CEBF32CB36Q35036663-4274D04E-D6E3-4A4C-AFF6-D8B5A294BD37Q35072638-B4BC39ED-A8DC-45E4-9E0C-885B5191B5AFQ35121597-57A898D3-D69A-44A3-BED0-B79E9829B2D0Q35683150-458B4887-9DFD-4AFA-A770-45CE12CB6533Q35894565-B3AA278E-7DC1-439B-A938-34F20A868DFCQ36043852-143E7D8A-B353-4698-9505-8FAEA7177981Q36275303-D2CAB2D4-BC17-4F2D-9DDF-09E7167BED6AQ36562896-694FBD5B-7DD8-4DFF-AEE7-2B5CCE7BB8A4Q36913771-1C107912-20DE-41EC-8D60-AFEAE302D721Q37201511-CD829F3F-5E6B-4C1C-A4C6-B6C55D210A24Q37339444-370D6F57-8275-417F-B3AE-8EFBF10B6C5AQ37351199-FA10B935-52BD-43EA-83B0-D0265D7511F9Q37551908-5B46409D-744C-4B19-8A08-44E5ED870BCEQ37799685-706AA3F7-EBCA-4360-B4C9-93DC62FA4499Q37863514-D7AECE67-5D54-4015-A40D-614EDC898695Q38311811-7780F8E2-3713-45D4-AFCD-347B006C03D2Q39367513-21030474-428A-4C1B-B8E8-03F8D4101741Q39692148-52C1D67E-4DC5-4616-AE06-8EF5DE857EB9Q42704760-A76C6BFA-AF6F-41EE-B83C-B3C5FED433FBQ45911404-6FC58F36-7466-4EDB-B427-D7A579895E82Q48531686-B4344E3F-BF79-4B96-8CD9-4AF0C3D6AF71Q51230315-C6751CCB-15D6-4D4B-957A-BD52099F995AQ55508245-738F8B8E-CE7A-4AD7-800C-32C3AFDF115DQ59210137-0CB4B8C4-E1E4-4F9A-83DA-2C3305967264
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chemokine signaling in cancer: one hump or two?
@en
Chemokine signaling in cancer: one hump or two?
@nl
type
label
Chemokine signaling in cancer: one hump or two?
@en
Chemokine signaling in cancer: one hump or two?
@nl
prefLabel
Chemokine signaling in cancer: one hump or two?
@en
Chemokine signaling in cancer: one hump or two?
@nl
P2860
P1476
Chemokine signaling in cancer: one hump or two?
@en
P2093
Joshua B Rubin
P2860
P304
P356
10.1016/J.SEMCANCER.2008.10.001
P577
2008-10-17T00:00:00Z